Hims & Hers Health (HIMS)

Generated: June 13, 2026

Yellow Dot

Statistics

Metric	Value
Last Close	$26.82
Blended Price Target	23.44
Blended Margin of Safety	-12.6% Overvalued
Rule of 40 (Next)	49.2%
Rule of 40 (Current)	41.6%
FCF-ROIC	7.6%
Sales Growth Next Year	41.6%
Sales Growth Current Year	34.0%
Sales 3-Year Avg	56.6%
Industry	Drug Manufacturers - Specialty & Generic

Analysis

Hims & Hers Health looks like a high‑quality, but still maturing, digital health business with a real platform and brand, not just a one‑product story. Its revenue base is largely subscription-driven, with millions of active subscribers across men’s and women’s health, which makes its top line more predictable than most consumer health peers.^[1]^[7] However, the sharp deceleration from extremely high growth in 2025 to low single‑digit growth in Q1 2026 underlines that the next phase will be harder and more execution‑dependent.^[1]^[7]

The company’s moat is emerging rather than entrenched. It benefits from brand recognition, a growing telehealth marketplace, and proprietary formulations, but operates in highly competitive categories where payers, regulators, and new entrants can quickly change the landscape. Leadership is founder‑led and has demonstrated an ability to scale, turn profitable at scale in 2025, and pivot the product mix, but the Q1 2026 margin compression shows they are still learning how to balance aggressive growth initiatives with profitability.^[1]^[7] Overall, the business appears durable if management continues to deepen clinical capabilities and diversify beyond any single blockbuster category.

What the Company Does

Hims & Hers Health operates a direct‑to‑consumer telehealth and wellness platform focused on conditions such as sexual health, hair loss, mental health, dermatology, and increasingly weight management.^[1]^[7] Customers interact via app or website, complete online consultations, and, if prescribed, receive branded or compounded medications and wellness products through partner pharmacies and mail delivery.^[1]^[7]

The company makes money primarily from recurring subscriptions for medications and treatments, supplemented by one‑time purchases of over‑the‑counter and wellness products.^[1]^[7] Management has emphasized the growth of “personalized” and compounded offerings, particularly in the U.S., and strong momentum in the Hers brand and weight‑loss category, which are becoming an increasingly important share of revenue, though recent disclosures do not break out precise percentages by segment.^[2]^[7]

Revenue Recurrence & Predictability

Revenue is predominantly subscription-based, as customers typically sign up for ongoing monthly medication shipments for chronic or recurring conditions like hair loss, acne, or sexual health.^[1]^[2] This model creates a relatively stable revenue base so long as churn remains controlled and patients continue to see benefit from treatments.^[1]^[2]

Management and external analyses describe the vast majority of revenue as recurring subscriptions, but recent company filings within the last six months do not give an updated explicit percentage.^[1]^[7] Given the subscription structure, multi‑month treatment plans, and large existing subscriber base reported for Q1 2026, revenue visibility is meaningfully higher than for a purely transactional retail business, though it remains exposed to subscriber growth trends and category‑specific shifts.^[1]

Revenue Growth Durability

The company is addressing a very large total addressable market across sexual health, dermatology, mental health, and metabolic/weight management, all areas where consumer demand and willingness to engage digitally remain strong.^[2]^[7] Structural tailwinds include increased comfort with telemedicine, stigma reduction around these conditions, and ongoing innovation in personalized and compounded medications.^[2]^[7]

However, growth durability now hinges on expanding into new geographies and broadening beyond any single “hero” product category. Q1 2026 results show revenue growth slowing sharply to low single digits year‑over‑year as weight‑loss products faced headwinds and the business absorbed a shift in product mix and pricing.^[1]^[6] This suggests that while above‑market growth is possible over the medium term, it will likely be more volatile than in the early hyper‑growth phase and dependent on continued product innovation and international expansion.^[1]^[6]^[7]

Economic Moat

Hims & Hers’ moat rests on a combination of brand, customer experience, and a vertically integrated telehealth‑to‑pharmacy model. The company has built consumer recognition around accessible, destigmatized care and has facilitated tens of millions of consultations, which gives it data and process know‑how that new entrants lack.^[2]^[7] Its proprietary and compounded formulations, as well as custom dosage combinations, are harder to commoditize than simple generic prescriptions.^[2]

That said, the moat is not yet deep. Telehealth platforms, pharmacies, and traditional providers are all pushing into similar categories, and customers can often switch to competing services with limited friction. Margin compression in Q1 2026, driven in part by the evolving economics of weight‑loss products and marketing intensity, suggests the company does not yet enjoy a durable cost advantage.^[1]^[6] The moat can widen if management continues to build differentiated clinical programs, strengthens stickiness through personalized regimens, and grows international scale, but competitive pressures remain significant.

Management & Leadership

Hims & Hers is founder-led: co‑founder Andrew Dudum serves as CEO and has been in that role since the company’s early days and through its public listing.^[7] Under his leadership, the company scaled from a niche men’s wellness brand into a multi‑category, dual‑gender telehealth platform and achieved full‑year GAAP profitability in 2025 before facing a more challenging margin picture in early 2026.^[1]^[7]

Insider ownership remains meaningful, aligning management with long‑term value creation, though exact recent percentages are not detailed in the latest earnings release and would need to be confirmed in the most recent proxy statement. Capital allocation has favored heavy reinvestment into marketing, technology, and new product categories, especially in compounded and weight‑loss treatments, alongside controlled international expansion.^[1]^[7] The willingness to reinvest aggressively is a strength, but the Q1 2026 pullback in profitability indicates the team is still calibrating the balance between growth and margins.

Key Risks

The most immediate risk is competitive and category concentration risk. Hims & Hers operates in crowded markets where traditional healthcare systems, pharmacy chains, startups, and big tech are all vying for digital health share. Its recent heavy emphasis on weight‑loss offerings, especially within the Hers brand, creates exposure to a single high‑profile category that could face rapid competitive shifts or changes in drug access and economics.^[2]^[6]

Regulatory and payer risk is also material. Telehealth, online prescribing, and compounded medications are closely watched by regulators, and changes in rules, enforcement priorities, or reimbursement practices could affect how Hims & Hers can market, prescribe, or ship certain treatments.^[2]^[6]^[7] Any high‑profile safety or compliance issue could damage the brand and trigger tighter oversight.

Operationally, scaling personalized care and pharmacy logistics at high volume is complex. The Q1 2026 margin decline shows that pricing, sourcing, and fulfillment economics can shift quickly as the product mix changes and as the company expands internationally.^[1]^[6] If management misjudges marketing efficiency, product economics, or supply partnerships, profitability and growth could both come under pressure.

Sources

Featured in GreenDot Stocks Analysis

GreenDot Stocks Screen Update — Week of June 13, 2026 June 13, 2026